EN DE
Watch AptaBio Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

AptaBio Therapeutics Inc (293780) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of AptaBio Therapeutics Inc stock KRW 3,285, price KRW 4,735, that is 30.6% below the price, quality 49 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7293780003

AT AptaBio Therapeutics Inc logo Thin data Nov 10, 2026

AptaBio Therapeutics Inc

293780 · KQ
Expensive, weak quality

Our calculation puts a fair price 31% below what the stock costs today.

Low debt
Revenue last quarter +43% vs. a year ago.
Quality 49/100
Mixed Growth (revenue 5y +61.1 %/yr in KRW)
Fair value 3,285 KRW · Overvalued
Negative free cash flow
Trails peers (1/8)
Narrow moat 16/100
Thin data
Estimate
Watch AptaBio Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

61,500 KRW 4,000 KRW Fair Value 3,285 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 4,000 KRW – 61,500 KRW · fair‑value band 2,464 KRW – 4,107 KRW · the 4,735 KRW price screens above the 3,285 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow AptaBio Therapeutics in your weekly email

Every Wednesday you see whether AptaBio Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases.

Show moreShow less

Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical needs.

The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX reagents for transfecting DNA or RNA into eukaryotic cells. The company was founded in 2009 and is based in Yongin-si, South Korea.

Stock analysis

AptaBio Therapeutics Inc (293780) currently trades at 4,735 KRW, while our estimate is 3,285 KRW, 31% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 2,464 KRW (bear) to 4,107 KRW (bull), the price of 4,735 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

AptaBio Therapeutics Inc reported revenue of 3.7B KRW in FY2025 versus 224M KRW in FY2021, a compound +101.6%/yr. Reported net income was −16.3B KRW in FY2025.

Key figures

Market cap 132B KRW (≈ $99.2M) Micro · P/S ratio 29.9 · EPS (TTM) −529.27 KRW · Return on equity −33.2% · Return on assets (EBIT) −20.5% (5-year average) · Operating margin −223% · Revenue (TTM) 4.8B KRW · Revenue growth (YoY) +42.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 55% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −31%, 293780 screens richer than that median.

Fair Value

Bear 2,464 KRW Fair Value 3,285 KRW Bull 4,107 KRW
Price 4,735 KRW · Downside -30.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 82
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 93
Debt, balance sheet and risk of trouble
Investment 96
Does it invest with discipline instead of growing at any price?
Low Volatility 35
How calm the share price moves, does not count
Price momentum 20
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 47
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,778.3% (2020) → −420.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

293780 screens overvalued: fair value 31% below the price. Compare with Merck KGaA →

Compare AptaBio Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −30.6% · Below median
Profitability
Return on assets −27.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 42.8% · Top 25%
Balance sheet
Debt / equity 0.29× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 2.80× · Pricier than median
P/S (12 months) 27.82× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)86 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs 293780
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs 293780
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs 293780
Haleon plc HLN $9.06 $8.62 −5% vs 293780
Merck KGaA MRK €149.35 €109.18 −27% vs 293780
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs 293780
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs 293780
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs 293780
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs 293780
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs 293780

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AptaBio Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "AptaBio Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/293780

Frequently asked questions

Is AptaBio Therapeutics Inc (293780) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 3,285 KRW versus a price of 4,735 KRW, about 31% lower (overvalued).
What is the fair value of 293780?
Our estimate for AptaBio Therapeutics Inc is 3,285 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 4,735 KRW.
What is the quality score of 293780?
AptaBio Therapeutics Inc has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AptaBio Therapeutics Inc (293780)?
Our calculated price target is the estimate of 3,285 KRW (as of Nov 10, 2026). Cautious scenario 2,464 KRW, optimistic scenario 4,107 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the AptaBio Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at 3,285 KRW, about 31% lower versus a price of 4,735 KRW (overvalued). Cautious scenario 2,464 KRW, optimistic scenario 4,107 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of AptaBio Therapeutics Inc (293780)?
AptaBio Therapeutics Inc reported trailing-twelve-month revenue of about 4.8B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of AptaBio Therapeutics Inc (293780)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AptaBio Therapeutics Inc it is 3,285 KRW per share (as of Nov 10, 2026), against a price of 4,735 KRW.
Is AptaBio Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 293780 trades above its calculated fair value: price 4,735 KRW, fair value 3,285 KRW, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 293780?
No. The price is what the market pays today (4,735 KRW); the fair value is what the company's own numbers justify (3,285 KRW). For AptaBio Therapeutics Inc the two are 1,450 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is AptaBio Therapeutics Inc worth?
The market values AptaBio Therapeutics Inc at about 132B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 4,735 KRW; our models calculate a fair value of 3,285 KRW per share.
What do the bullish and bearish scenarios say about 293780?
Our models span a range for AptaBio Therapeutics Inc: cautious scenario 2,464 KRW, base 3,285 KRW, optimistic 4,107 KRW per share (as of Nov 10, 2026, price 4,735 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of AptaBio Therapeutics Inc (293780)?
Balance-sheet figures for AptaBio Therapeutics Inc (as of Nov 10, 2026): return on equity −33.2%, debt of 0.29 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 293780 from its 52-week high?
AptaBio Therapeutics Inc trades at 4,735 KRW, about 55% below its 52-week high of 10,420 KRW and 18% above the low of 4,000 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 3,285 KRW is for.
Which stocks are comparable to AptaBio Therapeutics Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AptaBio Therapeutics Inc stock attractive at the current price?
The data as of Nov 10, 2026: price 4,735 KRW, calculated fair value 3,285 KRW (−31%), Quality Score 49/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. AptaBio Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AptaBio Therapeutics Inc (293780)?
The closing price on Nov 10, 2026 was 4,735 KRW. Our estimate is 3,285 KRW, about 31% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AptaBio Therapeutics Inc right now?
The price sits above even our optimistic bull case (4,107 KRW). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of AptaBio Therapeutics Inc

How large is the market capitalisation of AptaBio Therapeutics Inc (293780)?
The market capitalisation of AptaBio Therapeutics Inc is 132B KRW (≈ $99.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AptaBio Therapeutics Inc (293780)?
The price-to-sales ratio of AptaBio Therapeutics Inc is 29.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AptaBio Therapeutics Inc (293780)?
Earnings per share at AptaBio Therapeutics Inc are −529.27 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of AptaBio Therapeutics Inc (293780)?
The return on equity (ROE) of AptaBio Therapeutics Inc is −33.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AptaBio Therapeutics Inc (293780)?
On an EBIT basis the return on assets of AptaBio Therapeutics Inc is −20.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AptaBio Therapeutics Inc (293780)?
The operating margin of AptaBio Therapeutics Inc is −223% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AptaBio Therapeutics Inc (293780)?
Revenue at AptaBio Therapeutics Inc is growing +42.8% versus a year earlier (3y avg +324%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does AptaBio Therapeutics Inc (293780) generate?
The free cash flow of AptaBio Therapeutics Inc is −15.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch AptaBio Therapeutics Inc in the live analysis

One click puts AptaBio Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.